文献速递消化道肿瘤放疗放疗物理与技术

局部晚期食管鳞癌剂量递增放疗联合诱导及同步化疗的I/II期试验成熟结果

Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
PubMed 文献 · Radiat Oncol · 2021-03-23

这项前瞻性I/II期试验评估局部晚期食管鳞癌经诱导化疗后行剂量递增根治性放化疗的可行性与疗效。主要终点为1年局部区域无进展生存率。17例患者入组,16例接受根治性放化疗,9例(56%)达完全缓解;1年局部区域无进展生存率为59%,未达到预设的74%。治疗可耐受,无治疗相关死亡。

要点

  • 剂量递增放疗联合顺铂/伊立替康同步化疗可耐受,无治疗相关死亡。
  • 1年局部区域无进展生存率59%,未达到预设74%的II期假设。
  • 5年总生存率29%,长期生存与其它根治性放化疗研究相当。

核心结论

  • 局部晚期食管鳞癌经诱导化疗后行剂量递增放疗联合顺铂/伊立替康同步化疗可耐受,但未达到预设的1年局部区域无进展生存率74%。
  • 长期生存与其它使用伊立替康和顺铂的根治性放疗研究相当,但不优于近期采用50 Gy常规分割放疗联合紫杉醇或5-FU和铂类化合物的试验。

研究设计与样本

  • 前瞻性I/II期试验,2006年9月至2010年2月入组17例局部晚期食管鳞癌患者(男/女13/4,中位年龄59岁,范围48-66岁)。
  • 治疗方案:2周期诱导化疗(伊立替康、亚叶酸、5-FU每周,顺铂每2周,第1-6周和第8-13周),随后同步放化疗(顺铂和伊立替康,第14、15、17、18、20周)。
  • 放疗剂量递增分三档(60 Gy、66 Gy、72 Gy),常规分割,计划靶区借助18F-FDG-PET/CT勾画。
  • 主要终点为1年局部区域无进展生存率。

主要发现

  • 17例患者中1例在诱导化疗期间进展并接受手术,16例接受根治性放化疗,其中9例(56%)在放化疗结束后达完全缓解。
  • 1年、2年、3年和5年总生存率分别为77%[95%CI: 59-100]、53%[34-83]、41%[23-73]和29%[14-61]。
  • 1年、3年和5年局部区域无进展生存率分别为59%[40-88]、35%[19-67]和29%[14-61],对应的局部区域进展累积发生率分别为18%[4-39%]、35%[14-58%]和41%[17-64%]。
  • 无治疗相关死亡;诱导化疗期间3级毒性为中性粒细胞减少(41%)和腹泻(41%),联合治疗期间为中性粒细胞减少(62%)和血小板减少(25%)。

关键数值与推荐

  • 放疗剂量递增三档:60 Gy、66 Gy、72 Gy,常规分割。
  • 预设II期1年局部区域无进展生存率假设为74%,实际未达到。
  • 3级毒性发生率:诱导期间中性粒细胞减少41%、腹泻41%;联合治疗期间中性粒细胞减少62%、血小板减少25%。

临床怎么用

  • 该剂量递增方案可耐受,但未达到预设疗效假设,不作为常规推荐依据。
  • 长期生存与其它根治性放化疗研究相当,但未优于50 Gy常规分割联合紫杉醇或5-FU和铂类的方案。
  • PET/CT辅助靶区勾画和定期内镜随访可用于该人群的放疗计划与监测。

局限性

  • 样本量小(17例入组,16例接受根治性放化疗),为I/II期单臂试验。
  • 未达到预设的1年局部区域无进展生存率假设,疗效信号不足。
  • 长期生存未优于近期采用50 Gy常规分割联合紫杉醇或5-FU和铂类的试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This prospective phase I/II trial assessed feasibility and efficacy of dose-escalated definitive chemoradiation after induction chemotherapy in locally advanced esophageal cancer. Primary study endpoint was loco-regional progression-free survival at 1 year. METHODS: Eligible patients received 2 cycles of induction chemotherapy with irinotecan, folinic acid and 5-fluorouracil weekly and cisplatin every 2 weeks (weeks 1-6, 8-13) followed by concurrent chemoradiation with cisplatin and irinotecan (weeks 14, 15, 17, 18, 20). Radiotherapy dose escalation was performed in three steps (60 Gy, 66 Gy, 72 Gy) using conventional fractionation, planning target volumes were delineated with the aid of 18F-FDG-PET/CT scans. During follow-up, endoscopic examinations were performed at regular intervals. RESULTS: Between 09/2006 and 02/2010, 17 patients were enrolled (male/female:13/4, median age: 59 [range 48-66] years, stage uT3N0/T3N1/T4N1: 4/12/1). One patient progressed during induction chemotherapy and underwent surgery. Of 16 patients treated with definitive chemoradiotherapy, 9 (56%) achieved complete response after completion of chemoradiation. One-, 2-, 3- and 5-year overall survival rates (OS) were 77% [95%CI: 59-100], 53% [34-83], 41% [23-73], and 29% [14-61], respectively. Loco-regional progression-free survival at 1, 3, and 5 years was 59% [40-88], 35% [19-67], and 29% [14-61], corresponding cumulative incidences of loco-regional progressions were 18% [4-39%], 35% [14-58%], and 41% [17-64%]. No treatment related deaths occurred. Grade 3 toxicities during induction therapy were: neutropenia (41%), diarrhoea (41%), during combined treatment: neutropenia (62%) and thrombocytopenia (25%). CONCLUSIONS: Dose-escalated radiotherapy and concurrent cisplatin/irinotecan after cisplatin/irinotecan/5FU induction chemotherapy was tolerable. The hypothesized phase II one-year loco-regional progression free survival rate of 74% was not achieved. Long-term survival compares well with other studies on definitive radiotherapy using irinotecan and cisplatin but is not better than recent trials using conventionally fractionated radiotherapy ad 50 Gy with concurrent paclitaxel or 5FU and platinum compound. Trial registration The present trial was registered as a phase I/II trial at the EudraCT database: Nr. 2005-006097-10 ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006097-10/DE ) and authorized to proceed on 2006-09-25.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pöttgen C, Gkika E, Stahl M, et al. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. Radiat Oncol. 2021. PMID: 33757534. doi:10.1186/s13014-021-01788-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。